MetaVia

MetaVia CROIC

The Cash Return on Invested Capital (CROIC) of MetaVia (MTVA) as of Oct 30, 2026 is -283.29 %. In the previous year, Cash Return on Invested Capital (CROIC) was -306.41 % — a change of -7.54% (higher).

CROIC

-283.29 %

YoY

-7.54%

Last updated:

Cash Return on Invested Capital (CROIC) of MetaVia is 2025 -283.29 % . Cash Return on Invested Capital (CROIC) of MetaVia was 2024 -306.41 % . It decreases by -7.54% higher compared to the previous year.

The MetaVia CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
389.81 USD
Jan 1, 2019
-58.45 USD
Jan 1, 2020
-147.57 USD
Jan 1, 2021
-103.20 USD
Jan 1, 2022
-53.85 USD
Jan 1, 2023
-64.24 USD
Jan 1, 2024
-306.41 USD
Jan 1, 2025
-283.29 USD
The MetaVia CROIC history
YEARCROICYoY
-283.29 %-7.54%
-306.41 %+376.97%
-64.24 %+19.30%
-53.85 %-47.82%
-103.20 %-30.07%
-147.57 %+152.45%
-58.45 %-115.00%
389.81 %-302.56%
-192.44 %+259.54%
-53.52 %-158.68%
91.22 %-196.36%
-94.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

Cash Return on Invested Capital (CROIC) of MetaVia is -283.29 % in 2025.

Cash Return on Invested Capital (CROIC) of MetaVia changed from -306.41 % to -283.29 %, representing a -7.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) MetaVia since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s MetaVia with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — MetaVia

All Key Metrics — MetaVia